One of the things I learnt from Akceso – always welcome challenges
One of the things that I have learnt during my time with Akceso is that, if you believe that something is good and brings value, do not wait to start doing it.
The tool for full understanding of International Reference Pricing:
One of the things that I have learnt during my time with Akceso is that, if you believe that something is good and brings value, do not wait to start doing it.
This 5 years of research explores how external reference pricing (ERP, or also called as IRP – International Reference Pricing) is used to set pharmaceutical prices to improve affordability, but how its application may have negative consequences on patient access across certain countries.
The US Government just published its “Comprehensive Plan for Addressing High Drug Prices”. It lists a number of initiatives and ideas, but does NOT mention is International Reference Pricing – and this is good news for patients in the US and worldwide (and for manufacturers, too). – Read the Akceso Advisors reflection on a latest development in the US pharmaceuticals market based on Akceso Advisors’ research related to the impact of International Reference Pricing (IRP) on patient access and innovation.
Get in touch with us and schedule a demo.
Error: Contact form not found.
The PRiMA Headlines Newsletter provides a monthly overview of developments in Pricing, Reimbursement and Market Access developments across the globe. Since its launch in June 2015 we have covered more than 5,000 stories from over 100 countries.